{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:05:56Z","timestamp":1787241956821,"version":"build-2736575974"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["2021-10630"],"award-info":[{"award-number":["2021-10630"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioinform."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Ampicillin-resistant\n                      <jats:italic>Haemophilus influenzae<\/jats:italic>\n                      (\n                      <jats:italic>H. influenzae<\/jats:italic>\n                      ) has been recently designated as a medium-priority bacterial pathogen in 2024 by the World Health Organization (WHO). This pathogen is responsible for a wide range of infections, including sinusitis, acute otitis media, and pneumonia, as well as severe and life-threatening conditions such as bacteremia, meningitis, and epiglottitis. In this context, drug repurposing has emerged as an effective strategy, as the pharmacokinetic properties and safety profiles of approved drugs are already well established, allowing for faster development compared to conventional drug discovery approaches.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In the current study, U.S. Food and Drug Administration (FDA)-approved drugs with structural similarity to ampicillin were filtered and evaluated using\n                      <jats:italic>in silico<\/jats:italic>\n                      approaches. Their pharmacokinetic properties and antimicrobial potential were assessed. Molecular docking and simulation studies were conducted to evaluate binding affinities toward wild-type penicillin-binding protein 3 (PBP\n                      <jats:sub>3WT<\/jats:sub>\n                      ) and its common mutants (PBP3\n                      <jats:sub>N526K<\/jats:sub>\n                      and PBP3\n                      <jats:sub>R517H<\/jats:sub>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      An angiotensin II receptor blocker, valsartan, demonstrated strong binding affinity toward all three target proteins, with values of \u221211.8 kcal\/mol for PBP3\n                      <jats:sub>WT<\/jats:sub>\n                      , \u221211.4 kcal\/mol for PBP3\n                      <jats:sub>N526K<\/jats:sub>\n                      , and \u221211.1 kcal\/mol for PBP3\n                      <jats:sub>R517H<\/jats:sub>\n                      . The drug also exhibited strong intermolecular interactions and maintained stable binding with all three PBP3 variants during molecular dynamics simulations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      Based on these findings, valsartan is proposed as a potential PBP3 inhibitor targeting\n                      <jats:italic>H. influenzae<\/jats:italic>\n                      . The results support its candidacy for drug repurposing; however, further\n                      <jats:italic>in vitro<\/jats:italic>\n                      investigations are recommended to experimentally validate its antimicrobial activity.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fbinf.2026.1765472","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:36:40Z","timestamp":1777354600000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Repurposing the angiotensin II receptor blocker valsartan to inhibit penicillin-binding protein 3 and its mutants in Haemophilus influenzae: a comprehensive in silico approach"],"prefix":"10.3389","volume":"6","author":[{"given":"Srujal","family":"Kacha","sequence":"first","affiliation":[{"name":"Medical and Biological Computing Laboratory, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT)","place":["Vellore, Tamil Nadu, India"]},{"name":"Department of Biotechnology, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT)","place":["Vellore, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Arun","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT)","place":["Vellore, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelu","family":"Nargund","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT)","place":["Vellore, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Joshi","sequence":"additional","affiliation":[{"name":"Medical and Biological Computing Laboratory, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT)","place":["Vellore, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Mathpal","sequence":"additional","affiliation":[{"name":"Medical and Biological Computing Laboratory, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT)","place":["Vellore, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Ramaiah","sequence":"additional","affiliation":[{"name":"Medical and Biological Computing Laboratory, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT)","place":["Vellore, Tamil Nadu, India"]},{"name":"Department of Biosciences, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT)","place":["Vellore, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Anbarasu","sequence":"additional","affiliation":[{"name":"Medical and Biological Computing Laboratory, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT)","place":["Vellore, Tamil Nadu, India"]},{"name":"Department of Biotechnology, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT)","place":["Vellore, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12879-023-08930-5","article-title":"First global report about the prevalence of multi-drug resistant Haemophilus influenzae: a systematic review and meta-analysis","volume":"24","author":"Abavisani","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijantimicag.2018.09.018","article-title":"Antibacterial and antivirulence activities of auranofin against Clostridium difficile","volume":"53","author":"AbdelKhalek","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2147\/IJGM.S25989","article-title":"Update on the clinical utility and optimal use of cefditoren","volume":"455","author":"Aguilar","year":"2012","journal-title":"Int. J. Gen. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ijantimicag.2007.07.035","article-title":"Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens","volume":"30","author":"Alpuche","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B89","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1017\/S0950268812001082","article-title":"High prevalence of nasal carriage of \u03b2-lactamase-negative ampicillin-resistant Haemophilus influenzae in healthy children in Korea","volume":"141","author":"Bae","year":"2013","journal-title":"Epidemiol. Infect."},{"key":"B6","doi-asserted-by":"publisher","first-page":"105694","DOI":"10.1016\/j.micpath.2022.105694","article-title":"Non-steroidal anti-inflammatory drugs ketorolac and etodolac can augment the treatment against pneumococcal meningitis by targeting penicillin-binding proteins","volume":"170","author":"Basu","year":"2022","journal-title":"Microb. Pathog."},{"key":"B7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijantimicag.2004.09.016","article-title":"Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A \u03b2-haemolytic streptococci in 2002\u20132003","volume":"25","author":"Beekmann","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1016\/j.jmb.2019.07.010","article-title":"Novel and improved crystal structures of H. influenzae, E. coli and P. aeruginosa Penicillin-Binding protein 3 (PBP3) and N. gonorrhoeae PBP2: toward a better understanding of \u03b2-Lactam target-mediated resistance","volume":"431","author":"Bellini","year":"2019","journal-title":"J. Mol. Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1128\/jb.145.1.333-340.1981","article-title":"Evidence for involvement of penicillin-binding protein 3 in murein synthesis during septation but not during cell elongation","volume":"145","author":"Botta","year":"1981","journal-title":"J. Bacteriol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3390\/ijms23020811","article-title":"The SwissSimilarity 2021 web tool: novel chemical libraries and additional methods for an enhanced ligand-based virtual screening experience","volume":"23","author":"Bragina","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"10144","DOI":"10.1021\/jm501552x","article-title":"Trends and exceptions of physical properties on antibacterial activity for gram-positive and gram-negative pathogens","volume":"57","author":"Brown","year":"2014","journal-title":"J. Med. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1128\/AAC.46.7.2208-2218.2002","article-title":"Diversity of \u03b2-Lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae","volume":"46","author":"Dabernat","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/jac\/dkz018","article-title":"Repurposing disulfiram to target infections caused by non-tuberculous mycobacteria","volume":"74","author":"Das","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0167-0115(95)00085-P","article-title":"Binding of valsartan to mammalian angiotensin AT1 receptors","volume":"59","author":"de Gasparo","year":"1995","journal-title":"Regul. Pept."},{"key":"B16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/nm.2758","article-title":"A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target","volume":"18","author":"Debnath","year":"2012","journal-title":"Nat. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/antibiotics13080761","article-title":"A hunt for the resistance of haemophilus influnezae to beta-lactams","volume":"13","author":"Denizon","year":"2024","journal-title":"Antibiotics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"120091","DOI":"10.1016\/j.ijpharm.2020.120091","article-title":"Valsartan solid lipid nanoparticles integrated hydrogel: a challenging repurposed use in the treatment of diabetic foot ulcer, in-vitro\/in-vivo experimental study","volume":"592","author":"El-Salamouni","year":"2021","journal-title":"Int. J. Pharm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s10593-014-1496-1","article-title":"Prediction of the biological activity spectra of organic compounds using the Pass online web resource","volume":"50","author":"Filimonov","year":"2014","journal-title":"Chem. Heterocycl. Compd. (N Y)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"23136","DOI":"10.1038\/s41598-025-04409-2","article-title":"Exploring the potential role of GyrA inhibiting quinoline analog: an in silico study","volume":"15","author":"Ghosh","year":"2025","journal-title":"Sci. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10156-008-0632-1","article-title":"Prevalence of Haemophilus influenzae with resistant genes isolated from young children with acute lower respiratory tract infections in Nha Trang, Vietnam","volume":"14","author":"Gotoh","year":"2008","journal-title":"J. Infect. Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00203-025-04452-7","article-title":"Integrated machine learning, molecular dynamics, and DFT-based approach to elucidate the inhibitory effect of Ciprofloxacin analogues against fluoroquinolone-resistant Salmonella Typhi","volume":"207","author":"Guchhait","year":"2025","journal-title":"Arch. Microbiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"282ra49","DOI":"10.1126\/scitranslmed.3010286","article-title":"Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection","volume":"7","author":"He","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3390\/microorganisms11041018","article-title":"MALDI-TOF MS indirect beta-lactamase detection in ampicillin-resistant Haemophilus influenzae","volume":"11","author":"Hleba","year":"2023","journal-title":"Microorganisms"},{"key":"B25","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1128\/AAC.01952-12","article-title":"New life for an old drug: the anthelmintic drug Niclosamide inhibits Pseudomonas aeruginosa quorum sensing","volume":"57","author":"Imperi","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1136\/jcp.22.3.258","article-title":"Haemophili from eyes","volume":"22","author":"Ingham","year":"1969","journal-title":"J. Clin. Pathol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3390\/life11111260","article-title":"Characterization of Haemophilus influenzae strains with non-enzymatic resistance to \u03b2-Lactam antibiotics caused by mutations in the","volume":"11","author":"Jakubu","year":"2021","journal-title":"PBP3 Gene Czech Repub. 2010\u20132018"},{"key":"B28","doi-asserted-by":"publisher","first-page":"151626","DOI":"10.1016\/j.ijmm.2024.151626","article-title":"Evolution of mutations in the ftsI gene leading to amino acid substitutions in PBP3 in Haemophilus influenzae strains under the selective pressure of ampicillin and cefuroxime","volume":"316","author":"Jakubu","year":"2024","journal-title":"Int. J. Med. Microbiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/jac\/dkaf023","article-title":"Amino acid substitutions in PBP3 in Haemophilus influenzae strains, their phenotypic detection and impact on resistance to \u03b2-lactams","volume":"80","author":"Jakubu","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1185\/03007990802381505","article-title":"Surveillance study of the susceptibility of Haemophilus influenzae to various antibacterial agents in Europe and Canada","volume":"24","author":"Jansen","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s10096-009-0727-3","article-title":"Nationwide surveillance of antimicrobial resistance among Haemophilus influenzae and Streptococcus pneumoniae in intensive care units in Taiwan","volume":"28","author":"Jean","year":"2009","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/BF01691374","article-title":"Haemophilus influenzae: then and now","volume":"14","author":"Jordens","year":"1995","journal-title":"Eur. J. Clin. Microbiol. & Infect. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1080\/07391102.2020.1850356","article-title":"Repurposing of FDA approved drugs against Salmonella enteric serovar Typhi by targeting dihydrofolate reductase: an in silico study","volume":"40","author":"Joshi","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00203-026-04743-7","article-title":"Characterization and targeting of deleterious mutations in carbapenemase-producing Klebsiella pneumoniae: insights from variant calling, computer-aided drug design, and DFT analysis","volume":"208","author":"Joshi","year":"2026","journal-title":"Arch. Microbiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e02185-20","DOI":"10.1128\/mBio.02185-20","article-title":"Septal class A penicillin-binding protein activity and lD-Transpeptidases mediate selection of colistin-resistant lipooligosaccharide-deficient Acinetobacter baumannii","volume":"12","author":"Kang","year":"2021","journal-title":"mBio"},{"key":"B36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0732-8893(01)00331-5","article-title":"Activity of cefditoren against \u03b2-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis","volume":"42","author":"Karlowsky","year":"2002","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2217\/fmb-2019-0122","article-title":"Update on Drug-Repurposing: is it useful for tackling antimicrobial resistance?","volume":"14","author":"Kaul","year":"2019","journal-title":"Future Microbiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"105665","DOI":"10.1016\/j.micpath.2022.105665","article-title":"Repurposing of FDA approved drugs against uropathogenic Escherichia coli: in silico,in vitro, and in vivo analysis","volume":"169","author":"Kaur","year":"2022","journal-title":"Microb. Pathog."},{"key":"B90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/blr.2015.9999","article-title":"FDA\u2019s expedited approval mechanisms for new drug products","volume":"34","author":"Kepplinger","year":"2015","journal-title":"Biotechnol. Law Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1128\/AAC.05142-14","article-title":"Profiling of \u03b2-Lactam selectivity for penicillin-binding proteins in Streptococcus pneumoniae D39","volume":"59","author":"Kocaoglu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3201\/eid1603.090290","article-title":"Invasive Haemophilus influenzae Disease, Europe, 1996\u20132006","volume":"16","author":"Ladhani","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/jcp.56.5.344","article-title":"National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: Moxifloxacin compared with eight other antimicrobial agents","volume":"56","author":"Liebowitz","year":"2003","journal-title":"J. Clin. Pathol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s42003-021-02854-z","article-title":"Reversion of antibiotic resistance in multidrug-resistant pathogens using non-antibiotic pharmaceutical benzydamine","volume":"4","author":"Liu","year":"2021","journal-title":"Commun. Biol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s12879-023-08560-x","article-title":"Genomic classification and antimicrobial resistance profiling of Streptococcus pneumoniae and Haemophilus influenzae isolates associated with paediatric otitis media and upper respiratory infection","volume":"23","author":"Lobb","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1124\/mol.119.118042","article-title":"Structures of Mycobacterium tuberculosis penicillin-binding protein 3 in complex with five \u03b2-Lactam antibiotics reveal mechanism of inactivation","volume":"97","author":"Lu","year":"2020","journal-title":"Mol. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/cid\/cir735","article-title":"Current epidemiology and trends in invasive Haemophilus influenzae Disease--United States, 1989-2008","volume":"53","author":"MacNeil","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2165\/00003495-199754020-00009","article-title":"Valsartan","volume":"54","author":"Markham","year":"1997","journal-title":"Drugs"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1021\/jm0492002","article-title":"A bioavailability Score","volume":"48","author":"Martin","year":"2005","journal-title":"J. Med. Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1007\/s11030-025-11125-6","article-title":"Machine learning and cheminformatics-based Identification of lichen-derived compounds targeting mutant PBP4R200L in Staphylococcus aureus","volume":"29","author":"Mathpal","year":"2025","journal-title":"Mol. Divers."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/jac\/dkg474","article-title":"Contribution of \u03b2-lactamase and PBP amino acid substitutions to amoxicillin\/clavulanate resistance in \u03b2-lactamase-positive, amoxicillin\/clavulanate-resistant Haemophilus influenzae","volume":"52","author":"Matic","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1097\/00005344-199900001-00006","article-title":"Angiotensin II antagonism in clinical practice: experience with Valsartan","volume":"33","author":"McInnes","year":"1999","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1470320310370852","article-title":"Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects","volume":"12","author":"Miura","year":"2011","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"B52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jac\/18.Supplement_A.17","article-title":"The carrier state: haemophilus influenzae","volume":"18","author":"Moxon","year":"1986","journal-title":"J. Antimicrob. Chemother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/clinids\/12.1.75","article-title":"Global genetic structure and molecular epidemiology of encapsulated Haemophilus influenzae","volume":"12","author":"Musser","year":"1990","journal-title":"Clin. Infect. Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.22207\/JPAM.14.3.51","article-title":"Microbiological characterization and antibiotic susceptibility pattern of Haemophilus Influenzae isolates from a tertiary care Centre in South India","volume":"14","author":"Nair","year":"2020","journal-title":"J. Pure Appl. Microbiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10156-008-0623-2","article-title":"The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibility","volume":"14","author":"Niki","year":"2008","journal-title":"J. Infect. Chemother."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s10096-021-04247-w","article-title":"Haemophilus influenzae one day in Denmark: prevalence, circulating clones, and dismal resistance to aminopenicillins","volume":"40","author":"N\u00f8rskov-Lauritsen","year":"2021","journal-title":"Eur. J. Clin. Microbiol. & Infect. Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e22211","DOI":"10.1002\/ddr.22211","article-title":"Repurposing of drugs against bacterial infections: a pharmacovigilance\u2010based data mining approach","volume":"85","author":"Ohra","year":"2024","journal-title":"Drug Dev. Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1128\/AAC.49.7.2834-2839.2005","article-title":"Genetic approach to Study the relationship between Penicillin-Binding protein 3 mutations and Haemophilus influenzae \u03b2-Lactam resistance by using site-directed mutagenesis and gene recombinants","volume":"49","author":"Osaki","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1021\/jm700967e","article-title":"Physicochemical properties of antibacterial compounds: implications for drug discovery","volume":"51","author":"O\u2019Shea","year":"2008","journal-title":"J. Med. Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.1128\/AAC.01027-12","article-title":"Early insights into the interactions of different \u03b2-Lactam antibiotics and \u03b2-Lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3","volume":"56","author":"Papp-Wallace","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"113846","DOI":"10.1016\/j.biopha.2022.113846","article-title":"Drug repurposing \u2013 a search for novel therapy for the treatment of diabetic neuropathy","volume":"156","author":"Paul","year":"2022","journal-title":"Biomed. & Pharmacother."},{"key":"B91","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1038\/s41598-020-63199-x","article-title":"Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against","volume":"10","author":"Phanchana","year":"2020","journal-title":"Clostridioides difficile Sci Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1007\/s12033-024-01265-9","article-title":"Marine compound-carpatamide D as a potential inhibitor against TOP2A and its mutant D1021Y in colorectal cancer: insights from DFT, MEP and molecular dynamics simulation","volume":"67","author":"Priyamvada","year":"2025","journal-title":"Mol. Biotechnol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1574-6976.1999.tb00393.x","article-title":"Molecular determinants of the pathogenesis of disease due to non-typable Haemophilus influenzae","volume":"23","author":"Rao","year":"1999","journal-title":"FEMS Microbiol. Rev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1068-607X(97)00012-7","article-title":"Penicillin and ampicillin","volume":"4","author":"Raynor","year":"1997","journal-title":"Prim. Care Update Ob. Gyns."},{"key":"B65","doi-asserted-by":"crossref","DOI":"10.1101\/846428","volume-title":"Impact of different amino acid substitutions in penicillin-binding protein 3 on beta-lactam susceptibility in Haemophilus influenzae","author":"Reist","year":"2019"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1326121","DOI":"10.3389\/fddsv.2024.1326121","article-title":"Molecular determinant deciphering of MIC-guided RND efflux substrates in E. coli","volume":"4","author":"Revol-Tissot","year":"2024","journal-title":"Front. Drug Discov."},{"key":"B67","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.diagmicrobio.2018.10.009","article-title":"Detection of beta-lactamase-negative ampicillin resistance in Haemophilus influenzae in Belgium","volume":"93","author":"Schotte","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40121-023-00771-8","article-title":"\u03b2-Lactam resistance in ESKAPE pathogens mediated through modifications in Penicillin-Binding proteins: an overview","volume":"12","author":"Sethuvel","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1017\/S0031182012000169","article-title":"Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis","volume":"139","author":"Simarro","year":"2012","journal-title":"Parasitology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1093\/jac\/dkx277","article-title":"Biological evaluation of diphenyleneiodonium chloride (DPIC) as a potential drug candidate for treatment of non-tuberculous mycobacterial infections","volume":"72","author":"Singh","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B71","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3390\/microorganisms9050886","article-title":"Long term impact of conjugate vaccines on Haemophilus influenzae meningitis: narrative review","volume":"9","author":"Slack","year":"2021","journal-title":"Microorganisms"},{"key":"B72","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/00001813-200011000-00006","article-title":"Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients","volume":"11","author":"Smorenburg","year":"2000","journal-title":"Anticancer Drugs"},{"key":"B73","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/cid\/ciy187","article-title":"Current Epidemiology and Trends in Invasive Haemophilus influenzae Disease\u2014United States, 2009\u20132015","volume":"67","author":"Soeters","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12866-023-02926-6","article-title":"Molecular characterization of multidrug-resistant non-typeable Haemophilus influenzae with high-level resistance to cefuroxime, levofloxacin, and trimethoprim-sulfamethoxazole","volume":"23","author":"Su","year":"2023","journal-title":"BMC Microbiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1751-7176.2011.00518.x","article-title":"Angiotensin receptor blockers: pharmacology, efficacy, and safety","volume":"13","author":"Taylor","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"B76","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ijantimicag.2017.03.020","article-title":"Repurposing Ivacaftor for treatment of Staphylococcus aureus infections","volume":"50","author":"Thakare","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B77","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ijantimicag.2019.03.024","article-title":"Repurposing disulfiram for treatment of Staphylococcus aureus infections","volume":"53","author":"Thakare","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B78","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijantimicag.2015.12.016","article-title":"Repurposing auranofin for the treatment of cutaneous staphylococcal infections","volume":"47","author":"Thangamani","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0163-7258(85)90062-2","article-title":"Mode of action of \u03b2-lactam antibiotics","volume":"27","author":"Tipper","year":"1985","journal-title":"Pharmacol. Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e0172921","DOI":"10.1128\/AAC.01729-21","article-title":"Effects of Inactivation of d,d- Transpeptidases of Acinetobacter baumannii on bacterial growth and susceptibility to \u03b2-lactam antibiotics","volume":"66","author":"Toth","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B81","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1128\/CMR.00040-06","article-title":"Antimicrobial resistance in Haemophilus influenzae","volume":"20","author":"Tristram","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1128\/AAC.45.6.1693-1699.2001","article-title":"Association of amino acid substitutions in penicillin-binding protein 3 with \u03b2-Lactam resistance in \u03b2-Lactamase-Negative ampicillin-resistant Haemophilus influenzae","volume":"45","author":"Ubukata","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cir268","article-title":"Nontypeable Haemophilus influenzae invasive disease in the Netherlands: a retrospective surveillance Study 2001-2008","volume":"53","author":"van Wessel","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1172\/JCI31547","article-title":"Valsartan lowers brain \u03b2-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease","volume":"117","author":"Wang","year":"2007","journal-title":"J. Clin. Investigation"},{"key":"B85","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0140-6736(09)61203-4","article-title":"Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates","volume":"374","author":"Watt","year":"2009","journal-title":"Lancet"},{"key":"B86","volume-title":"WHO bacterial priority pathogens list 2024","year":"2024"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nm.4184","article-title":"Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen","volume":"22","author":"Xu","year":"2016","journal-title":"Nat. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1574-6976.2007.00095.x","article-title":"Penicillin-binding proteins and \u03b2-lactam resistance","volume":"32","author":"Zapun","year":"2008","journal-title":"FEMS Microbiol. Rev."}],"container-title":["Frontiers in Bioinformatics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2026.1765472\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:36:44Z","timestamp":1777354604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2026.1765472\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":91,"alternative-id":["10.3389\/fbinf.2026.1765472"],"URL":"https:\/\/doi.org\/10.3389\/fbinf.2026.1765472","relation":{},"ISSN":["2673-7647"],"issn-type":[{"value":"2673-7647","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1765472"}}